Abatacept Injection

DRUG5 trials

Sponsors

Johns Hopkins University, Fundacion Clinic per a la Recerca Biomédica, Duke University, University of Erlangen-Nürnberg Medical School, St George's, University of London

Conditions

Juvenile Idiopathic ArthritisMyasthenia GravisPalindromic Rheumatism, WristRheumatoid Arthritis

Early Phase 1

Trial of Orencia in Patients With Myasthenia Gravis

TerminatedNCT03059888

Johns Hopkins UniversityMyasthenia Gravis

Start: 2017-04-12End: 2019-07-15Updated: 2019-11-22

Phase 2

TOLERA: Tolerance Enhancement in RA

University of Erlangen-Nürnberg Medical SchoolRheumatoid Arthritis

Start: 2019-10-07End: 2022-12-01Target: 20Updated: 2019-10-09

Phase 3

Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

CompletedNCT03841357

Duke UniversityJuvenile Idiopathic Arthritis

Start: 2019-10-29End: 2025-01-22Updated: 2026-01-23

Phase 4

EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)

CompletedNCT03669367

Fundacion Clinic per a la Recerca BiomédicaPalindromic Rheumatism, Wrist

Start: 2019-06-03End: 2024-09-30Updated: 2025-02-26

Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)

CompletedNCT04255134

St George's, University of LondonRheumatoid Arthritis

Start: 2020-09-07End: 2022-10-26Updated: 2023-05-18

Related Papers

Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial

Nature Medicine2026-05-14

Assessing the effects of distinct biologic therapies on rheumatoid arthritis pain by nociceptive, neuropathic and nociplastic pain components: a randomised feasibility study.

2024-05-16